Literature DB >> 9735126

Papillary carcinoma of the thyroid gland: treatment based on risk group definition.

B Cady1.   

Abstract

This article outlines the current controversy regarding the extent of treatment of papillary carcinoma of the thyroid. It emphasizes that following general principles in surgical oncology, surgeons doing endocrine cancer management should scale the extensiveness of their operative procedure to the risk of the cancer. The majority of patients with papillary carcinoma fall into a low-risk group with a 1% or less risk of death over a period of many years. It is illogical to treat these patients in the same fashion as patients who have a 50% risk of death in a shorter period of time. The various components of the risk assignment systems are outlined and emphasized to give surgeons the confidence to use risk category in their selection of surgical and adjuvant treatment of papillary carcinoma of the thyroid.

Entities:  

Mesh:

Year:  1998        PMID: 9735126

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  14 in total

1.  The indices of body size and aggressiveness of papillary thyroid carcinoma.

Authors:  Ju-Yeon Kim; Eun-Jung Jung; Sang-Ho Jeong; Chi-Young Jeong; Young-Tae Ju; Young-Jun Lee; Soon-Chan Hong; Sang-Kyeong Choi; Woo-Song Ha; Soon-Tae Park
Journal:  J Korean Surg Soc       Date:  2011-04-12

2.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

3.  Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).

Authors:  Ian D Hay; Tammi R Johnson; Suneetha Kaggal; Megan S Reinalda; Nicole M Iniguez-Ariza; Clive S Grant; Siobhan T Pittock; Geoffrey B Thompson
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 4.  Prognostic biomarkers in thyroid cancer.

Authors:  Paula Soares; Ricardo Celestino; Miguel Melo; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 5.  Current practice in patients with differentiated thyroid cancer.

Authors:  Martin Schlumberger; Sophie Leboulleux
Journal:  Nat Rev Endocrinol       Date:  2020-12-18       Impact factor: 43.330

6.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

7.  Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure.

Authors:  Yukie Enomoto; Keisuke Enomoto; Shinya Uchino; Hiroshi Shibuya; Shin Watanabe; Shiro Noguchi
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

8.  The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.

Authors:  E M Triviño Ibáñez; M A Muros; E Torres Vela; J M Llamas Elvira
Journal:  Endocrine       Date:  2015-07-30       Impact factor: 3.633

9.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

10.  Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts.

Authors:  Paolo Miccoli; Michele N Minuto; Clara Ugolini; Erica Panicucci; Piero Berti; Marco Massi; Fulvio Basolo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.